Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

Keystone, Edward C; Schiff, Michael H; Kremer, Joel M; Kafka, Shelly; Lovy, Michael; DeVries, Todd; Burge, Daniel J

Keystone, Edward C; Schiff, Michael H; Kremer, Joel M; Kafka, Shelly; Lovy, Michael; DeVries, Todd; Burge, Daniel J.

Affiliation

Keystone EC; Mt. Sinai Hospital, Toronto, Ontario, Canada. edkeystone@mtsinai.on.ca

Arthritis Rheum ; 50(2): 353-63, 2004 Feb.

Article in En | MEDLINE | ID: mdl-14872476

Subject(s)

Antirheumatic Agents/therapeutic use; Arthritis, Rheumatoid/drug therapy; Immunoglobulin G/therapeutic use; Receptors, Tumor Necrosis Factor/therapeutic use; Adult; Aged; Aged, 80 and over; Antirheumatic Agents/administration & dosage; Antirheumatic Agents/pharmacokinetics; Arthritis, Rheumatoid/physiopathology; C-Reactive Protein/analysis; Double-Blind Method; Drug Administration Schedule; Etanercept; Female; Health Status; Humans; Immunoglobulin G/administration & dosage; Injections, Subcutaneous; Joints/drug effects; Joints/pathology; Joints/physiopathology; Male; Middle Aged; Pain Measurement; Placebos; Receptors, Tumor Necrosis Factor/administration & dosage; Severity of Illness Index; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Immunoglobulin G / Receptors, Tumor Necrosis Factor / Antirheumatic Agents Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Arthritis Rheum Year: 2004 Type: Article Affiliation country: Canada

Search on Google

XML

PubMed Links